收稿日期: 2023-12-06
网络出版日期: 2024-07-09
基金资助
北京市科学技术协会青年人才托举工程(BYESS2022170);首都医科大学“本科生科研创新”项目(XSKY2023298)
Clinical value of joint detection of cerebrospinal fluid and blood routine indicators in differentiating between multiple gliomas and primary central nervous system lymphoma
Received date: 2023-12-06
Online published: 2024-07-09
目的 探讨脑脊液(CSF)和血常规多项指标联合检测对多发性脑胶质瘤(MCG)与原发性中枢神经系统淋巴瘤(PCNSL)鉴别诊断的临床价值。 方法 回顾性分析首都医科大学附属天坛医院2017年11月至2023年3月收治的62例MCG患者和56例PCNSL患者临床资料、CSF及血常规检测指标,并分析有意义指标单独及联合应用鉴别诊断MCG与PCNSL的临床价值。 结果 MCG组CSF细胞总数、CSF白细胞数、CSF蛋白(CSF: pro)、乳酸、血常规中性粒细胞计数、中性粒细胞% 水平显著高于PCNSL组(P < 0.05);PCNSL组CSF糖(CSF: Glu)、CSF氯(CSF: cl)、血常规淋巴细胞计数、嗜酸性粒细胞、淋巴细胞%、嗜酸性粒细胞% 水平显著高于MCG组(P < 0.05)。CSF细胞总数、CSF白细胞、CSF: pro、乳酸、血常规中性粒细胞计数、中性粒细胞% 鉴别诊断MCG和PCNSL的AUC为:0.900、0.899、0.797、0.867、0.828、0.772;灵敏度为:72.4%、77.6%、63.8%、67.2%、72.4%、82.8%;特异度为:97.1%、100.0%、88.2%、91.2%、88.2%、64.7%。此外,CSF细胞总数、CSF白细胞、CSF:pro、血常规中性粒细胞计数和中性粒细胞% 指标联合检测鉴别诊断MCG和PCNSL的AUC为0.919,敏感度和特异度为77.6%和100.0%。 结论 脑脊液学指标CSF细胞总数、CSF白细胞、CSF:pro及血常规指标中性粒细胞计数和中性粒细胞% 联合检测鉴别诊断MCG和PCNSL具有较高的临床应用价值。
关键词: 多发性脑胶质瘤; 原发性中枢神经系统淋巴瘤; 脑脊液; 血常规; 鉴别诊断
姜华 , 张丽敏 , 王丹 , 韩平 , 孙越红 , 李玉文 , 张晨曦 , 姜文灿 , 李虓 , 赵晖 . 脑脊液联合血常规检测在多发性脑胶质瘤与原发性中枢神经系统淋巴瘤鉴别诊断中的临床价值[J]. 实用医学杂志, 2024 , 40(13) : 1864 -1868 . DOI: 10.3969/j.issn.1006-5725.2024.13.017
Objective To investigate the clinical significance of combined cerebrospinal fluid (CSF) and routine blood parameter analysis in differentiating between multiple cerebral glioma (MCG) and primary central nervous system lymphoma (PCNSL). Methods We Rretrospectively analyzed the clinical data, CSF and routine blood indicators levels of 62 MCG patients and 56 PCNSL patients admitted to Beijing Tiantan Hospital, Capital Medical University from November 2017 to March 2023. Additionally, we assessed the diagnostic value of individual meaningful indicators as well as their combinations in distinguishing between MCG and PCNSL. Results The levels of CSF total cell count, CSF white cell count, CSF: pro, lactate, routine bloodperipheral neutrophil count, and neutrophil percentage were significantly higher in the MCG group than in the PCNSL group (P < 0.05); while the levels of CSF: Glu, CSF: cl, routine blood lymphocyte count, eosinophil, lymphocyte percentage, and eosinophil percentage were significantly higher in the PCNSL group than in the MCG group (P < 0.05). The AUCs of CSF cell count, CSF white cell count, CSF: pro, lactate, routine blood neutrophil count, neutrophil percentage for differentiating MCG from PCNSL were 0.900, 0.899, 0.797, 0.867, 0.828 and 0.772 respectively; sensitivities were 72.4%, 77.6%, 63.8%, 67.2%, 72.4%, 82.8%, 77.6% and 81%, with sensitivities of 97.1%, 100%, 88.2%, 91.2%, 88.2%, 64.7%, 100% and 94.1%, respectively. In addition, the combined detection of CSF total cell count, CSF white cell count, CSF: pro, routine blood neutrophil count and neutrophil percentage in CSF had an AUC of 0.919 for differentiating MCG from PCNSL, with a sensitivity and specificity of 77.6% and 100%, respectively. Conclusions Combined detection of CSF indicators including CSF total cell count, CSF white cell count, CSF: pro, along with routine blood markers such as neutrophil count and neutrophil percentage, holds significant clinical utility for differentiating between MCG and PCNSL.
| 1 | DANDACHI D, OSTROM Q T, CHONG I, et al. Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data[J]. Cancer Causes Control, 2019, 30(5): 477-488. doi:10.1007/s10552-019-01144-8 |
| 2 | PONS-ESCODA A, NAVAL-BAUDIN P, VELASCO R, et al. Imaging of lymphomas involving the CNS: an update-review of the full spectrum of disease with an emphasis on the world health organization classifications of CNS tumors 2021 and hematolymphoid tumors 2022[J]. AJNR Am J Neuroradiol, 2023, 44(4): 358-366. doi:10.3174/ajnr.a7795 |
| 3 | MENDEZ J S, OSTROM Q T, GITTLEMAN H, et al. The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades[J]. Neuro Oncol, 2018, 20(5): 687-694. doi:10.1093/neuonc/nox187 |
| 4 | HOANG XUAN K, DECKERT M, FERRERI A J M, et al. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)[J]. Neuro Oncol, 2023, 25(1): 37-53. doi:10.1093/neuonc/noac196 |
| 5 | 李盼盼, 张卓. 42例原发性中枢神经系统淋巴瘤患者预后影响因素分析[J]. 中国癌症杂志, 2021, 31(12): 1194-1201. |
| 6 | DI CARLO D T, CAGNAZZO F, BENEDETTO N, et al. Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis[J]. Neurosurg Rev, 2019, 42(2): 263-275. doi:10.1007/s10143-017-0928-7 |
| 7 | 陆禹辰. 多发性脑胶质瘤的临床特点及预后分析[D]. 乌鲁木齐:新疆医科大学, 2023. |
| 8 | CAIRNCROSS G, WANG M, SHAW E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402[J]. J Clin Oncol, 2013, 31(3): 337-343. doi:10.1200/jco.2012.43.2674 |
| 9 | 范梦珂, 张旭东, 赵璐, 等. 原发性中枢神经系统淋巴瘤的CT影像特征分析[J]. 临床血液学杂志, 2023, 36(11): 819-823. |
| 10 | 张少茹, 周云舒, 张若弟, 等. 多参数MRI影像组学模型鉴别高级别胶质瘤与原发性中枢神经系统淋巴瘤的价值[J]. 磁共振成像, 2023, 14(10): 53-64. doi:10.12015/issn.1674-8034.2023.10.010 |
| 11 | 韩梦婷, 孙振亮. 脑胶质瘤的治疗现状[J]. 中国基层医药, 2021, 28(10): 1596-1600. doi:10.3760/cma.j.issn1008-6706.2021.10.036 |
| 12 | 尹硕, 陈峰, 郑晓红, 等. 新药疗法推动原发性中枢神经系统淋巴瘤的治疗进展[J]. 首都医科大学学报, 2023, 44(5): 775-781. doi:10.3969/j.issn.1006-7795.2023.05.011 |
| 13 | 高敏, 陈彦斌, 高强. MRI鉴别诊断原发性中枢神经系统淋巴瘤与多发性脑胶质瘤的临床意义[J]. 贵州医药, 2021, 45(11): 1794-1795. doi:10.3969/j.issn.1000-744X.2021.11.065 |
| 14 | 张玉梅, 范炜, 鲁君, 等. MRI在多发性脑胶质瘤与原发性中枢神经系统淋巴瘤鉴别诊断中的应用[J]. 中国卫生标准管理, 2020, 11(22): 82-85. doi:10.3969/j.issn.1674-9316.2020.22.031 |
| 15 | 徐帆, 李泉. 磁共振成像对原发性中枢神经系统淋巴瘤与多发性脑胶质瘤鉴别诊断的价值分析[J]. 实用医技杂志, 2020, 27(10): 1321-1322. |
| 16 | HUANG L, SHAO D, WANG Y, et al. Human body-fluid proteome: Quantitative profiling and computational prediction[J]. Brief Bioinform, 2021, 22(1): 315-333. doi:10.1093/bib/bbz160 |
| 17 | SIM J, PARK J, MOON J S, et al. Dysregulation of inflammasome activation in glioma[J]. Cell Commun Signal, 2023, 21(1): 239. doi:10.1186/s12964-023-01255-5 |
| 18 | LIN W, GAO J, ZHANG H, et al. Identification of molecular subtypes based on inflammatory response in lower-grade glioma[J]. Inflamm Regen, 2022, 42(1): 29. doi:10.1186/s41232-022-00215-9 |
| 19 | BASHEER A S, ABAS F, OTHMAN I, et al. Role of Inflammatory mediators, macrophages, and neutrophils in glioma maintenance and progression: mechanistic understanding and potential therapeutic applications[J]. Cancers, 2021, 13(16): 4226. doi:10.3390/cancers13164226 |
| 20 | SHEN F, ZHANG Y, YAO Y, et al. Proteomic analysis of cerebrospinal fluid: toward the identification of biomarkers for gliomas[J]. Neurosurg Rev, 2014, 37(3): 367-380. doi:10.1007/s10143-014-0539-5 |
| 21 | HE K, WANG Y, XIE X, et al. Prediction of proteins in cerebrospinal fluid and application to glioma biomarker identification[J]. Molecules, 2023, 28(8): 3617. doi:10.3390/molecules28083617 |
| 22 | 孙虎, 沈峥, 郑玲燕, 等. 脑胶质瘤患者脑脊液中HOXA13、Plexin-B2的定量分析及生物学意义研究[J]. 中国现代医生, 2017, 55(15): 23-26. |
| 23 | YAMANOI Y, FUJII M, MURAKAMI Y, et al. Soluble protein tyrosine phosphatase receptor type Z (PTPRZ) in cerebrospinal fluid is a potential diagnostic marker for glioma[J]. Neurooncol Adv, 2020, 2(1): 55. doi:10.1093/noajnl/vdaa055 |
| 24 | YAMASAKI F, KURISU K, KAJIWARA Y, et al. Magnetic resonance spectroscopic detection of lactate is predictive of a poor prognosis in patients with diffuse intrinsic pontine glioma[J]. Neuro Oncol, 2011, 13(7): 791-801. doi:10.1093/neuonc/nor038 |
| 25 | 高丹丹, 刘君星, 辛华, 等. 大鼠脑胶质瘤细胞培养上清液的收集及其乳酸含量变化和意义[J]. 黑龙江医药科学, 2015, 38(3): 44-47. doi:10.3969/j.issn.1008-0104.2015.03.022 |
| 26 | NIGROVIC L E, KIMIA A A, SHAH S S, et al. Relationship between cerebrospinal fluid glucose and serum glucose[J]. N Engl J Med, 2012, 366(6): 576-578. doi:10.1056/nejmc1111080 |
| 27 | 陈映, 俞志鹏, 夏莉君. 脑脊液糖持续低下的原发性中枢神经系统淋巴瘤1例[J]. 中国神经精神疾病杂志, 2018, 44(9): 559-561. |
/
| 〈 |
|
〉 |